KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Income towards Parent Company (2016 - 2025)

Jazz Pharmaceuticals has reported Income towards Parent Company over the past 15 years, most recently at $203.5 million for Q4 2025.

  • Quarterly Income towards Parent Company rose 6.47% to $203.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$263.5 million through Dec 2025, down 146.9% year-over-year, with the annual reading at -$355.5 million for FY2025, 163.28% down from the prior year.
  • Income towards Parent Company was $203.5 million for Q4 2025 at Jazz Pharmaceuticals, down from $251.4 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $251.4 million in Q3 2025 and troughed at -$718.4 million in Q2 2025.
  • The 5-year median for Income towards Parent Company is $70.4 million (2023), against an average of $9.1 million.
  • Biggest five-year swings in Income towards Parent Company: plummeted 641.94% in 2022 and later skyrocketed 1109.01% in 2023.
  • Tracing JAZZ's Income towards Parent Company over 5 years: stood at -$32.3 million in 2021, then plummeted by 641.94% to -$240.0 million in 2022, then soared by 139.42% to $94.6 million in 2023, then skyrocketed by 101.98% to $191.1 million in 2024, then grew by 6.47% to $203.5 million in 2025.
  • According to Business Quant data, Income towards Parent Company over the past three periods came in at $203.5 million, $251.4 million, and -$718.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.